DASL-HiCaP

Trial DASL-HiCaP
Cancer Type Prostate Cancer
Hospital(s) Belfast City Hospital
Information

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer

Posted in .